{
    "nct_id": "NCT00086138",
    "title": "Depression in Alzheimer's Disease (DIADS-2)",
    "status": "COMPLETED",
    "last_update_time": "2017-02-28",
    "description_brief": "The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.",
    "description_detailed": "Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks. Visits include neuropsychological testing. Caregivers are asked to are the patient on a Daily Affect Diary for 6 weeks during the study period. Telephone followup is done at weeks 36 and 48. Both groups receive caregiver support/education.",
    "phase": [
        "PHASE2",
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "recruitmentDetails": "Participants were recruited from memory clinics at five academic centers in the United States.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo",
                    "description": "Participants will receive placebo matched to sertraline\n\nPlacebo: Placebo designed to mimic sertraline taken daily for 24 weeks"
                },
                {
                    "id": "FG001",
                    "title": "Sertraline",
                    "description": "Participants will receive sertraline at a target dose of 100mg daily.\n\nSertraline (Zoloft): Sertraline: range of 25 to 125 mg per day for 24 weeks"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "64"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "67"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "60"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "64"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Sertraline",
                    "description": "Participants will receive sertraline at a target dose of 100mg daily.\n\nSertraline (Zoloft): Sertraline: range of 25 to 125 mg per day for 24 weeks"
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "Participants will receive placebo matched to sertraline\n\nPlacebo: Placebo designed to mimic sertraline taken daily for 24 weeks"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "67"
                        },
                        {
                            "groupId": "BG001",
                            "value": "64"
                        },
                        {
                            "groupId": "BG002",
                            "value": "131"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Customized",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "title": "Age",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "76.5",
                                            "spread": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "78.2",
                                            "spread": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "77.3",
                                            "spread": "8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex/Gender, Customized",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Female",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "40"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "71"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Male",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "60"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC)",
                    "description": "At each study visit, based on patient examination and caregiver interview, clinicians rated overall impression of clinical change from baseline using the modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change index (mADCS-CGIC), which in addition to the original scale incorporates a global rating of mood and associated symptoms of depression. The mADCS-CGIC uses a seven-point Likert scale, with scores ranging from 1 (\"much better\") to 7 (\"much worse\"), with a score of 4 being \"no change\".",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "Measured at Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sertraline",
                            "description": "Participants will receive sertraline at a target dose of 100mg daily.\n\nSertraline (Zoloft): Sertraline: range of 25 to 125 mg per day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Participants will receive placebo matched to sertraline\n\nPlacebo: Placebo designed to mimic sertraline taken daily for 24 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "67"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "64"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "\"much worse\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"worse\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"a bit worse\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "9"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"no change\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "11"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"a bit better\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"better\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "21"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "\"much better\"",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The statistical analyses compared data collected from the CGIC of participants who received sertraline who had a score equal to or better than the CGIC of participants who received the placebo intervention.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.98",
                            "statisticalMethod": "Chi-squared",
                            "paramType": "Odds Ratio (OR)",
                            "paramValue": "1.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.52",
                            "ciUpperLimit": "1.97"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Remission According to Cornell Scale for Depression in Dementia Scale",
                    "description": "The Cornell Scale for Depression in Dementia (CSDD), a 19-item scale measuring the severity of depression in dementia, utilizing input from both the caregiver and the participant. CSDD scores were imputed for 2 participants for week 2, 4 participants for week 4, 7 participants for week 8, and 12 participants for week 12.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "percentage of participants",
                    "timeFrame": "Measured at Weeks 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Sertraline",
                            "description": "Participants will receive sertraline at a target dose of 100mg daily.\n\nSertraline (Zoloft): Sertraline: range of 25 to 125 mg per day for 24 weeks"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Participants will receive placebo matched to sertraline\n\nPlacebo: Placebo designed to mimic sertraline taken daily for 24 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "67"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "64"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "33"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER",
                            "pValue": "0.11",
                            "statisticalMethod": "Chi-squared",
                            "paramType": "Odds Ratio (OR)",
                            "paramValue": "2.06",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.84",
                            "ciUpperLimit": "5.04"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Sertraline",
                    "description": "Participants will receive sertraline at a target dose of 100mg daily.\n\nSertraline (Zoloft): Sertraline: range of 25 to 125 mg per day for 24 weeks",
                    "seriousNumAffected": 13,
                    "seriousNumAtRisk": 67,
                    "otherNumAffected": 44,
                    "otherNumAtRisk": 67
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Participants will receive placebo matched to sertraline\n\nPlacebo: Placebo designed to mimic sertraline taken daily for 24 weeks",
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 64,
                    "otherNumAffected": 26,
                    "otherNumAtRisk": 64
                }
            ],
            "seriousEvents": [
                {
                    "term": "Pneumonia/respiratory infection",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 64
                        }
                    ]
                },
                {
                    "term": "Neurologic",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 64
                        }
                    ]
                },
                {
                    "term": "Musculoskeletal",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 64
                        }
                    ]
                },
                {
                    "term": "Cardiac",
                    "organSystem": "Cardiac disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 64
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 36,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 22,
                            "numAtRisk": 64
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 44,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 26,
                            "numAtRisk": 64
                        }
                    ]
                },
                {
                    "term": "Dry mouth",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 37,
                            "numAtRisk": 67
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 23,
                            "numAtRisk": 64
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Paul Rosenberg",
                "organization": "JHU",
                "email": "prosenb9@jhmi.edu",
                "phone": "410-550-9883"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "sertraline (Zoloft)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The DIADS-2 trial is a randomized, placebo-controlled study testing the antidepressant sertraline for treatment of depression in people with Alzheimer disease (explicitly designed to treat depressive symptoms, not to modify AD pathology). \ue200cite\ue202turn0search7\ue202turn0search1\ue201",
        "Mechanism / drug type (Act): Sertraline (Zoloft) is a selective serotonin reuptake inhibitor (SSRI) \u2014 a small\u2011molecule antidepressant that increases synaptic serotonin to treat mood disorders. It is not a biologic targeting amyloid or tau. \ue200cite\ue202turn1search0\ue202turn1search3\ue201",
        "Trial findings (supporting classification): DIADS-2 compared sertraline (target dose ~100 mg/day) to placebo for depression in AD and found no clear superiority for sertraline on primary depression outcomes and noted higher adverse events in the sertraline group\u2014consistent with this being a neuropsychiatric symptom trial rather than a disease\u2011modifying trial. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Mapping to category definitions \u2014 this intervention is (a) a small\u2011molecule antidepressant used to relieve depressive symptoms in AD (neuropsychiatric symptom management), not a biologic targeting Alzheimer pathology nor a cognitive\u2011enhancer per se. Therefore the correct category is 'neuropsychiatric symptom improvement'. No ambiguity that would place it in the other three categories. \ue200cite\ue202turn0search1\ue202turn1search0\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The DIADS-2 trial tested the antidepressant sertraline (Zoloft) specifically to treat depressive symptoms in people with Alzheimer disease, i.e., a neuropsychiatric symptom\u2011management trial rather than a disease\u2011modifying trial. \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "Act: Sertraline is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT) to increase synaptic serotonin \u2014 a classical neurotransmitter/monoaminergic mechanism (not an anti-amyloid or anti-tau biologic). Therefore the most specific CADRO category is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search2\ue202turn0search7\ue201",
        "Reflect: This classification aligns with CADRO because the intervention acts on monoaminergic neurotransmission (serotonin reuptake inhibition) to relieve depressive symptoms, not to target core AD pathologies (amyloid, tau, inflammation, etc.). The trial\u2019s negative efficacy findings and adverse-event profile further support that this was a symptomatic/neuropsychiatric intervention rather than a disease\u2011modifying one. \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "Web search results (supporting citations):",
        "- DIADS-2 randomized, placebo-controlled trial report (summary and outcomes): \"Sertraline for the treatment of depression in Alzheimer disease\" (PubMed/PMC). \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "- DIADS-2 subgroup/outcome analyses (PubMed). \ue200cite\ue202turn0search0\ue201",
        "- Sertraline pharmacology and mechanism (SSRI; inhibits serotonin reuptake): Purdue/clinical drug summary and review articles. \ue200cite\ue202turn0search2\ue202turn0search7\ue201"
    ]
}